- Home
- ZJYL vs VTYX Comparison
ZJYL vs VTYX Comparison
Compare ZJYL & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZJYL
- VTYX
- Stock Information
- Founded
- ZJYL 2006
- VTYX 2018
- Country
- ZJYL China
- VTYX United States
- Employees
- ZJYL N/A
- VTYX N/A
- Industry
- ZJYL Industrial Specialties
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- ZJYL Consumer Discretionary
- VTYX Health Care
- Exchange
- ZJYL Nasdaq
- VTYX Nasdaq
- Market Cap
- ZJYL 142.5M
- VTYX 154.9M
- IPO Year
- ZJYL 2023
- VTYX 2021
- Fundamental
- Price
- ZJYL $1.04
- VTYX $1.94
- Analyst Decision
- ZJYL
- VTYX Buy
- Analyst Count
- ZJYL 0
- VTYX 4
- Target Price
- ZJYL N/A
- VTYX $11.33
- AVG Volume (30 Days)
- ZJYL 555.3K
- VTYX 1.9M
- Earning Date
- ZJYL 07-26-2024
- VTYX 02-25-2025
- Dividend Yield
- ZJYL N/A
- VTYX N/A
- EPS Growth
- ZJYL N/A
- VTYX N/A
- EPS
- ZJYL 0.02
- VTYX N/A
- Revenue
- ZJYL $20,125,185.00
- VTYX N/A
- Revenue This Year
- ZJYL N/A
- VTYX N/A
- Revenue Next Year
- ZJYL N/A
- VTYX N/A
- P/E Ratio
- ZJYL $48.77
- VTYX N/A
- Revenue Growth
- ZJYL 0.75
- VTYX N/A
- 52 Week Low
- ZJYL $0.70
- VTYX $1.67
- 52 Week High
- ZJYL $16.60
- VTYX $11.48
- Technical
- Relative Strength Index (RSI)
- ZJYL 53.24
- VTYX 39.33
- Support Level
- ZJYL $0.76
- VTYX $2.10
- Resistance Level
- ZJYL $1.08
- VTYX $2.61
- Average True Range (ATR)
- ZJYL 0.19
- VTYX 0.18
- MACD
- ZJYL 0.03
- VTYX -0.05
- Stochastic Oscillator
- ZJYL 42.34
- VTYX 5.67
About ZJYL JIN MEDICAL INTERNATIONAL LTD.
Jin Medical International Ltd offers rehabilitation equipment. It is primarily engaged in the design, development, manufacturing, and sales of wheelchair and other living aids products to be used by people with disabilities or impaired mobility. The Company's products are sold to distributors in both China and in overseas markets. Its product offerings comprise Wheelechaire serirs, Bath products, oxygen machines, nursing products, and conlo products.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.